Dublin, Ireland-based Jazz Pharmaceuticals has recruited Kim Sablich as executive vice president, general manager of North America, effective June 1, 2020. In this role, Kim will lead Jazz’ newly formed North American regional business structure, including Canada and the US, which brings together Medical Affairs, Commercial and Market Access teams for North America to create strategically aligned and integrated customer-facing organisation. She will report to Daniel Swisher, president and chief operating officer. Kim joins Jazz from Myovant Sciences, where she is chief commercial officer. Prior to this, she held the roles of VP, Primary Care Marketing in the US for GlaxoSmithKline.

Santen is proud to welcome Dr Sophia Pathai as the new VP of Medical Affairs EMEA. As a qualified ophthalmologist and clinical scientist, Sophia has practised medical and surgical ophthalmology in varied clinical environments worldwide. She also spent a year on the ORBIS Flying Eye Hospital as a staff ophthalmologist and continues to work with non-profit organisations such as Médecins Sans Frontières to improve eye care in settings such as Myanmar, India and sub-Saharan Africa. In her new role, Sophia is responsible for leading the strategic development of Medical Affairs EMEA.This will involve leading medical engagement by leveraging digital media. She will also focus on driving excellence in key business processes, such as integrated evidence planning. Most recently, Sophia served as the Medical Affairs Director at Johnson & Johnson Surgical Vision (Asia Pacific & Japan), where she led the medical affairs strategy for the launch of three surgical ophthalmic devices.

Stabilitech Biopharma has today announced the addition of Professor Jeffrey Almond to its board, as the firm steps up its efforts in search of a vaccine for COVID-19. Jeffrey is an Oxford Martin Visiting Fellow with the Oxford Martin Programme on Vaccines and former VP, head of Discovery Research and External R&D at Sanofi Pasteur and Visiting Professor at the William School of Pathology, University of Oxford. He has been published extensively, especially in the field of virology. “I’m really excited by Professor Almond’s appointment. He brings with him a wealth of knowledge and expertise in developing successful vaccines and I am confident that his knowledge will strengthen our team,” commented the firm's chairman Wayne Channon.

Charlotte Chorley has recently joined AI drug repurposing biotech, Healx, as Head of Communications. An experienced communications and campaigns expert, Charlotte joins from Google Health, where she led on UK patient engagement, industry partnerships and external communications. Prior to that role, she oversaw several communications and engagement programmes at DeepMind, the world leader in artificial intelligence research, and led new business and campaign partnerships in her role at digital agency, Shape History. In addition to communications, Charlotte is Chair of Trustees for Fumble – a digital media charity which provides young people with authoritative information on sexual health, well-being and relationships.

Alantra, a global leader in investment banking and asset management, has recruited four professionals to reinforce its global technology practice, including a team of three IT Services and Public Cloud specialists and a senior software banker. Michael Lenoce (managing director, New York), Renee Shaening (managing director, San Francisco) and Joe Nau (associate, Boston) have joined from MVP Capital, where they formed the investment banking technology team. Additionally, the technology team adds Dragan Manoev (managing director, San Francisco), an investment banking veteran with more than 20 years' experience, who joined Alantra from Lazard’s TMT & Software team.

Digital health services provider Doctor Care Anywhere has named Ben Kent as its new chief operating officer. Ben has joined the business to support the delivery of its objective to become a leading global player in digital healthcare. He will focus on continuing to develop DCA’s strategic presence and scaling up additional value streams, including for its virtual specialist capability and mental health services. According to the firm, Ben has a 'proven track record' of delivering strategic transformation and business development in healthcare, having held a range of C-suite roles at both regulated health and insurance businesses, including as chief financial officer at Simplyhealth and Group Director of Finance at Bupa.

The UK genomic tools developer RevoluGen has appointed Sir John Chisholm as non-executive chairman. Sir John was most recently executive chairman of Genomics England in which role he oversaw the world-leading 100,000 Genome Project, which led to the UK being the first country to introduce Genomic Medicine into its health system. His expertise will help steer the development of RevoluGen’s business including the optimal application of its leading Fire Monkey/Fire Flower products for DNA extraction. “Sir John Chisholm will prove to be a great addition to our armoury as he brings a wealth of genomic experience and expertise to RevoluGen,” said the firm's chief executive Pieter Haitsma Mulier.

Syncona, a healthcare company focused on founding, building and funding global leaders in life sciences, has named Danny Bar-Zohar as Syncona Partner. In this role, Danny will leverage his expertise in clinical development, regulatory environments and medical affairs to help Syncona further build and establish its portfolio of life sciences companies. He has almost 15 years of experience in the pharma and biotech sector, having worked at Teva Pharmaceutical Industries and Novartis Pharma after practising medicine for over a decade. He joins from Novartis where, most recently, he was global head of Clinical Development and Analytics.